Biobide’s aim is to accelerate R&D process for Pharma, Biotech, Chemical, Cosmetic and Nutraceutical companies minimizing risks through our zebrafish services, adding value to clients R&D&i mainly in preclinical area.
We are a CRO specialized in zebrafish working under Good Laboratory Practice (GLP) and thanks to our automated and innovative tools, we have developed and validated time and cost effective Toxicity and Efficacy Assays, as well as disease models to be used in preclinical stages.
The followed strategy is based on:
to develop, in an environment of Good Laboratory Practice, reliable and relevant assays for our Customers, Regulatory Bodies and, ultimately, for Human Health based on an experimental design and interpretation of results supported by a first-rate technology platform and innovative tools.
to integrate into our processes the capabilities required to understand and apply advances in genetic and physiological research, automation, image analysis and all other areas of knowledge which impact on our business model.
having a network of alliances and strategic partnerships to develop and launch together new solutions to the market.
to achieve our Customers and Regulatory bodies being the promoters of our services.
Biobide was founded in 2005 in order to resolve the main problem that contemporary biotechnological and pharmaceutical companies were facing: how to deal with the low success rate in marketing new drugs and block busters. In 2014, the company was acquired by the Bionaturis Group. During 2018, Bionaturis acquired ADL Biopharma by a reverse acquisition.
The Newco after the integration, ADL Bionatur Solutions is a biotech European leader focused in R&D and manufacturing high value fermentation products for human and animal health. ADL Bionatur Solutions is quoted on the alternative Spanish stock exchange for SME (MaB, ticker ADL).
Celia took a PhD. in Biochemistry and Molecular Biology after studying the regulation of protein initiation factors in neurons. She manages different projects related with development of models, as well as some general and organ specific toxicities such as teratogenicity or ototoxicity.